Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-intensity immunosuppression versus modern standard care in poor-prognosis diffuse cutaneous systemic sclerosis: A propensity-matched study.

Journal of autoimmunity·2026
Same author

Safety and effectiveness of tocilizumab in systemic sclerosis: a multicentre French-Italian study.

RMD open·2026
Same author

Real-world efficacy and safety profile of four JAK inhibitors in rheumatoid arthritis: a French single-center observational study.

Clinical rheumatology·2026
Same author

[Correlation between carotid atheroma and DAS28 gamma GT score in rheumatoid arthritis in an African black population].

Annales de cardiologie et d'angeiologie·2026
Same author

Successful treatment of multicentric reticulohistiocytosis with JAK inhibitor: a case series.

RMD open·2026
Same author

18F-fluorodeoxyglucose PET/CT uptake characteristics in immune checkpoint inhibitor-induced polymyalgia rheumatica compared to idiopathic polymyalgia rheumatica.

Rheumatology (Oxford, England)·2026
Same journal

Greater trochanteric bursal distension with intra-bursal rice bodies: an unusual MRI presentation.

Joint bone spine·2026
Same journal

Evaluating the Impact of a Rheumatologist-led Comorbidity Review in Patients with Inflammatory Arthritis.

Joint bone spine·2026
Same journal

What cumulative glucocorticoid dose should trigger sparing strategies in polymyalgia rheumatica?

Joint bone spine·2026
Same journal

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update.

Joint bone spine·2026
Same journal

Multimodal imaging evaluation of the entheses in spondyloarthritis.

Joint bone spine·2026
Same journal

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update. What's new?

Joint bone spine·2026
See all related articles

Related Experiment Video

Updated: Jun 29, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Systemic sclerosis: an update in 2008.

Yannick Allanore1, Jérôme Avouac, André Kahan

  • 1Paris Descartes University, Medical Faculty, Department of Rheumatology A, Cochin Hospital, AP-HP and INSERM U781, Necker Hospital, Paris, France. yannick.allanore@cch.aphp.fr

Joint Bone Spine
|October 8, 2008
PubMed
Summary
This summary is machine-generated.

Systemic sclerosis treatment is complex, affecting blood vessels, immunity, and fibroblasts. Cardiovascular drugs improve outcomes, but pulmonary fibrosis remains a challenge.

More Related Videos

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

Related Experiment Videos

Last Updated: Jun 29, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

Area of Science:

  • Rheumatology and Immunology
  • Dermatology
  • Cardiovascular Medicine

Background:

  • Systemic sclerosis pathogenesis involves vascular, immune, and fibroblast abnormalities.
  • Disease complexity complicates therapeutic strategies.
  • Recent data show decreased mortality, potentially linked to cardiovascular drug use.

Purpose of the Study:

  • To review current and future therapeutic options for systemic sclerosis.
  • To discuss the impact of cardiovascular drugs on systemic sclerosis prognosis.
  • To highlight challenges in treating pulmonary fibrosis in systemic sclerosis.

Main Methods:

  • Review of epidemiological data on systemic sclerosis mortality.
  • Analysis of treatment efficacy for various systemic sclerosis involvements.
  • Discussion of current and emerging therapeutic strategies.

Main Results:

  • Cardiovascular drugs have improved prognosis for kidney, heart, and pulmonary vascular involvements.
  • Pulmonary fibrosis remains a therapeutic challenge despite immunosuppressor trials.
  • Systemic sclerosis management requires addressing broad biological abnormalities and disease duration.

Conclusions:

  • Improved cardiovascular care has positively impacted systemic sclerosis mortality.
  • Pulmonary fibrosis treatment in systemic sclerosis requires novel approaches.
  • Future systemic sclerosis therapies must integrate multifaceted disease characteristics.